Overview

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

Status:
Recruiting
Trial end date:
2024-08-09
Target enrollment:
Participant gender:
Summary
This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy
Phase:
Phase 2
Details
Lead Sponsor:
Chipscreen Biosciences, Ltd.
Treatments:
Capecitabine
Chiauranib